Lessons Learned
multiple myeloma, dermatologic adverse, Toxicity
MULTIPLE MYELOMA
Study enrollment for front-line therapy in multiple myeloma can be limited by the rapidly expanding landscape of available approved drugs in this setting.Toxicity rates for this regimen were higher than expected, with >40% of patients experiencing Grade 3 dermatologic adverse events, possibly impacting drug efficacy.The response rates and survival data with the combination of metronomic cyclophosphamide with ixazomib and dexamethasone for the treatment of multiple myeloma in the front-line setting do not support future study of this regimen in this space.